AtaiBeckley
 | |
| Type | Public |
|---|---|
| Nasdaq: ATAI | |
| Industry | Biotechnology |
| Predecessor | atai Life Sciences Beckley Psytech |
| Founded | 2018 (as atai Life Sciences) 2019 (as Beckley Psytech) 2025 (as AtaiBeckley) |
| Founder | Christian Angermayer Srinivas Rao Cosmo Feilding Mellen |
| Headquarters | , United States |
Key people | Srinivas Rao, CEO Christian Angermayer, Chairman |
| Website | www |
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021.[1][2][3] Beckley Psytech, a private company, was founded in 2019.[4][5][6] In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY.[7] The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
The company's pharmaceutical candidates include mebufotenin (5-MeO-DMT; BPL-003; intranasal) for treatment-resistant depression, dimethyltryptamine (DMT; VLS-01; oromucosal film) for treatment-resistant depression, and (R)-midomafetamine ((R)-MDMA; EMP-01) for social anxiety disorder. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression.[6][8] Other previous candidates of Atai Life Sciences prior to its merger into AtaiBeckley included ibogaine (IBX-210, DMX-1002), EGX-121 (a non-tryptamine new chemical entity), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).[9][10][11]
Peter Thiel was a major investor in Atai Life Sciences before it merged into AtaiBeckley.[1] Atai Life Sciences also had a 22.4% stake in Compass Pathways.[1][2]
In July 2026, it was announced that Eli Lilly and Company, the world's largest pharmaceutical company, would acquire AtaiBeckley for US$2.8 billion.[12][13][14]
See also
[edit]References
[edit]- 1 2 3 Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (1 September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry" (PDF). Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. ISSN 2831-4425.
- 1 2 "ATAI Life Sciences". Psychedelic Alpha. 6 October 2023. Retrieved 27 February 2025.
- ↑ Ponieman, Natan (14 June 2021). "Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers". finance.yahoo.com. Retrieved 24 June 2021.
- ↑ Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry". Psychedelic Medicine. 1 (3). Mary Ann Liebert, Inc.: 150–165. doi:10.1089/psymed.2023.0013.
- ↑ Henning, Eyk (2 June 2025). "Thiel-Backed Psychedelic Drugmaker Atai to Buy Rival Beckley". Bloomberg. Bloomberg L.P. Retrieved 18 June 2026.
- 1 2 AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update (Report). AtaiBeckley Inc. 6 March 2026. Retrieved 18 June 2026 – via U.S. Securities and Exchange Commission.
- ↑ "AtaiBeckley Completes Redomiciliation to the United States" (Press release). AtaiBeckley Inc. 31 December 2025. Retrieved 18 June 2026 – via GlobeNewswire.
- ↑ Taylor, Phil (5 November 2025). "Psychedelic merger to create AtaiBeckley completes". Pharmaphorum. Retrieved 18 May 2026.
- ↑ "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 27 February 2025.
- ↑ "Delving into the Latest Updates on ATAI Life Sciences AG with Synapse". Synapse. 23 January 2025. Retrieved 27 February 2025.
- ↑ "Programs". atai Life Sciences. 13 January 2025. Archived from the original on 16 January 2025. Retrieved 27 February 2025.
- ↑ Taylor, Nick Paul (16 July 2026). "Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market". Fierce Biotech. Retrieved 16 July 2026.
- ↑ Tolomia, Cris (16 July 2026). "Eli Lilly to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion". Quartz. Retrieved 16 July 2026.
- ↑ Psychedelic Alpha (16 July 2026). "Breaking: World's Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion". Psychedelic Alpha. Retrieved 16 July 2026.